Lipocine (LPCN) had an infringement case related to its oral testosterone replacement drug in a US court brought by Clarus Therapeutics thrown out.
The case filed at US District Court in Delaware was dismissed as the court found that there was no immediate reason to hear the case given Lipocine’s failure to receive Food and Drug Administration market approval for LPCN-1021, Clarus said in a statement on Thursday.
Clarus said it won’t take any further action unless LPCN-1021 is approved by the FDA. Clarus will have the option to refile its patent infringement lawsuit when that approval is given, according to the court, the company said.
Clarus is developing drugs for men’s health and it’s preparing to begin sales of Jatenzo, an oral testosterone replacement therapy.
Lipocine shares fell nearly 9% on Thursday.